Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2017

Open Access 01-08-2017 | Leading Article

Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives

Authors: Maciej Kupczyk, Piotr Kuna

Published in: Drugs | Issue 12/2017

Login to get access

Abstract

Prostaglandin D2 (PGD2) released by degranulating mast cells is believed to play a key role in orchestrating mechanisms of inflammation in allergies and asthma. The biological effects of PGD2 are mediated by D-prostanoid (DP1), CRTH2 (DP2), and thromboxane prostanoid (TP) receptors. The CRTH2 receptor is involved in induction of migration and activation of T helper type 2 (Th2) lymphocytes, eosinophils, and basophils; up-regulation of adhesion molecules; and promotion of pro-inflammatory Th2-type cytokines (interleukin [IL]-4, 5, 13), whereas the DP receptor is associated with relaxation of smooth muscles, vasodilation, inhibition of cell migration, and apoptosis of eosinophils. A number of CRTH2/PGD2 receptor antagonists have been investigated in asthma and allergic diseases. The CRTH2 antagonist (OC000459) or dual CRTH2 and TP receptor antagonist (ramatroban) were effective in reducing eosinophilia, nasal mucosal swelling, and clinical symptoms of allergic rhinitis, with the latter drug registered for clinical use in this indication. OC000459 and setipiprant reduced the late but not early phase of response in an allergen challenge in atopic asthmatics. In persistent asthma, some molecules induced limited improvement in lung function, quality of life, and asthma symptoms (OC000459, BI671800), but in other trials with AMG 853 and AZ1981 these findings were not confirmed. The clear discrepancy between animal studies and clinical efficacy of CRTH2 antagonism in allergic rhinitis, and lack of efficacy in a general cohort of asthmatics, highlight the issue of patient phenotyping. There is no doubt that the PGD2/CATH2/DP1 pathway plays a key role in allergic inflammation and further studies with selective or combined antagonisms in well defined cohorts of patients are needed.
Literature
1.
Kupczyk M, Lundstrom S, Dahlen B, et al. Lipid mediators in severe asthma. Eur Respir Mon. 2011;51:218–35.
2.
Pettipher R, Hansel TT. Antagonists of the prostaglandin D2 receptor CRTH2. Drug News Perspect. 2008;21:317–22.CrossRefPubMed
3.
Schuligoi R, Sturm E, Luschnig P, et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology. 2010;85:372–82.CrossRefPubMed
4.
Fujitani Y, Kanaoka Y, Aritake K, et al. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol. 2002;168:443–9.CrossRefPubMed
5.
Mesquita-Santos FP, Vieira-de Abreu A, Calheiros AS, et al. Cutting edge: prostaglandin D2 enhances leukotriene C4 synthesis by eosinophils during allergic inflammation: synergistic in vivo role of endogenous eotaxin. J Immunol. 2006;176:1326–30.CrossRefPubMed
6.
Herrerias A, Torres R, Serra M, et al. Activity of the cyclooxygenase 2—prostaglandin E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2. J Inflamm. 2009;6:30.CrossRef
7.
Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program. Am J Respir Crit Care Med. 2011;183:299–309.CrossRefPubMed
8.
Gyles SL, Xue L, Townsend ER, et al. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cells supernatants. Immunology. 2006;119:362–8.CrossRefPubMedPubMedCentral
9.
Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 1997;155:1856–63.CrossRefPubMed
10.
Pierzchalska M, Szabo Z, Sanak M, et al. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients with special reference to aspirin-induced asthma. J Allergy Clin Immunol. 2003;111:1041–8.CrossRefPubMed
11.
Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med. 2006;12:148–58.CrossRefPubMed
12.
Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193:255–61.CrossRefPubMedPubMedCentral
13.
Monneret G, Gravel S, Diamond M, et al. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood. 2001;98:1942–8.CrossRefPubMed
14.
Nagata K, Hirai H. The second PGD2 receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids. 2003;69:169–77.CrossRefPubMed
15.
16.
Hsu SC, Chen LC, Kuo ML, et al. Novel SNPs in a candidate gene, CRTH2, for allergic diseases. Genes Immun. 2002;3:114–6.CrossRefPubMed
17.
Gazi L, Gyles S, Rose J, et al. Δ12-Prostaglandin D2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes. Prostaglandins Other Lipid Mediat. 2005;75:153–67.CrossRefPubMed
18.
Murray JJ, Tonnel AB, Brash AR, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986;315:800–4.CrossRefPubMed
19.
Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D2 pathway upregulation: relation to asthma severity, control and TH2 inflammation. J Allergy Clin Immunol. 2013;131:1504–12.CrossRefPubMedPubMedCentral
20.
Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol. 1999;162:1278–86.PubMed
21.
Xue L, Gyles SL, Wettey FR, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005;175:6531–6.CrossRefPubMed
22.
Xue L, Barrow A, Pettipher R. Interaction between prostaglandin D2 and chemoattractant receptor-homologous expressed n Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells. Clin Exp Immunol. 2009;156:126–33.CrossRefPubMedPubMedCentral
23.
Xue L, Barrow A, Pettipher R. Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol. 2009;182:7580–6.CrossRefPubMed
24.
Nagata K, Hirai H, Tanaka K, et al. CRTH2, an orphan receptor of T-helper-2 cells, is expressed on basophils and responds to mast cell-derived factor(s). FEBS Lett. 1999;459:195–9.CrossRefPubMed
25.
Gervais FG, Cruz RPG, Chateauetneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001;108:982–8.CrossRefPubMed
26.
Schroder R, Xue L, Konya V, et al. PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. PLoS One. 2012;7(3):e33329.CrossRefPubMedPubMedCentral
27.
Heinemann A, Schuligoi R, Sabroe I, et al. Δ12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization form the bone marrow and primes eosinophils for chemotaxis. J Immunol. 2003;170:4752–8.CrossRefPubMed
28.
Hirai H, Tanaka K, Takano S, et al. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol. 2002;168:981–5.CrossRefPubMed
29.
Shirasaki H, Kikuchi M, Kanaizumi E, et al. Accumulation of CRTH2-positive leukocytes in human allergic nasal mucosa. Ann Allergy Asthma Immunol. 2009;102:110–5.CrossRefPubMed
30.
Nantel F, Fong C, Lamontagne S, et al. Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa. Prostaglandins Other Lipid Mediat. 2004;73:87–101.CrossRefPubMed
31.
Stubbs VEL, Schratl P, Hartnell A, et al. Indomethacin causes prostaglandin D2-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem. 2002;277(29):26012–20.CrossRefPubMed
32.
Gervais FG, Morello JP, Beaulieu C, et al. Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005;67(6):1834–9.CrossRefPubMed
33.
Shiraishi Y, Asano K, Niimi K, et al. Cyclooxygenase-2/prostaglandin D2/CRTH2 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation. J Immunol. 2008;180:541–9.CrossRefPubMed
34.
Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science. 2000;287:2013–7.CrossRefPubMed
35.
Kabashima K, Narumiya S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids. 2003;69:187–94.CrossRefPubMed
36.
Larsson AK, Hagfjard A, Dahlen SE, Adner M. Prostaglandin D2 induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig. Eur J Pharmacol. 2011;669(1–3):136–42.CrossRefPubMed
37.
Arimura A, Yasui K, Kishino J, et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther. 2001;29:411–9.
38.
Hirai H, Abe H, Tanaka K, et al. Gene structure and functional properties of mouse CRTH2, a prostaglandin D2 receptor. Biochem Biophys Res Commun. 2003;307:797–802.CrossRefPubMed
39.
Uller L, Mathiesen JM, Alenmyr L, et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007;8:16–25.CrossRefPubMedPubMedCentral
40.
Spik I, Brenuchon C, Angeli V, et al. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol. 2005;174(6):3703–8.CrossRefPubMed
41.
Shichijo M, Sugimoto H, Nagao K, et al. Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats. J Pharmacol Exp Ther. 2003;307(2):518–25.CrossRefPubMed
42.
Shiraishi Y, Asano K, Nakajima T, et al. Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther. 2005;312(3):954–60.CrossRefPubMed
43.
Stebbins KJ, Broadhead AR, Correa LD, et al. Therapeutic efficacy of AM 156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol. 2010;638:142–9.CrossRefPubMed
44.
Gervais FG, Sawyer N, Stocco R, et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol. 2011;79(1):69–76.CrossRefPubMed
45.
Lukacs NW, Berlin AA, Franz-Bacon K, et al. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2008;295(5):L767–79.CrossRefPubMedPubMedCentral
46.
Chevalier E, Stock J, Fisher T, et al. Cutting edge: chemoattractant receptor-homologous molecule expressed on TH2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol. 2005;175(4):2056–60.CrossRefPubMed
47.
Satoh T, Moroi R, Aritake K, et al. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol. 2006;177(4):2621–9.CrossRefPubMed
48.
Gonzalo J, Qiu Y, Coyle AJ, Hodge MR. CRTH2(DP2) and not the DP1 receptor mediate allergen induced mucus production and airway hyperresponsiveness. Am J Respir Crit Care Med. 2005;163(5):A811.
49.
Safholm J, Manson ML, Bood J, et al. Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J Allergy Clin Immunol. 2015;136(5):1232–9.CrossRefPubMed
50.
Norel X, Labat C, Gardiner PJ, Brink C. Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations. Br J Pharmacol. 1991;104:591–5.CrossRefPubMedPubMedCentral
51.
52.
Dogne JM, de Leval X, Benoit P, et al. Thromboxane A2 inhibition. Therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11–7.CrossRefPubMed
53.
Ishizuka T, Matsui T, Okamoto Y, et al. Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor. Cardiovasc Drug Rev. 2004;22(2):71–90.CrossRefPubMed
54.
Narita S, Asakura K, Kataura A. Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Int Arch Allergy Immunol. 1996;109:161–6.CrossRefPubMed
55.
Terada N, Yamakoshi T, Hasegawa M, et al. The effect of ramatroban (BAY u 3405), a thromboxane A2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis. Acta Oto-Laryngol. 2009;118(537):32–7.
56.
Nagai H, Takeda H, Yamaguchi S, et al. The effect of a thromboxane A2 receptor antagonist BAY-u-3405 on experimental allergic reactions. Prostaglandins. 1995;50:75–87.CrossRefPubMed
57.
Sugimoto H, Shichijo M, Iino T, et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther. 2003;305:347–52.CrossRefPubMed
58.
Terada N, Yamakoshi T, Hasegawa M, et al. Effect of a thromboxane A2 receptor antagonist, ramatroban (BAY u3405), on inflammatory cells, chemical mediators and non-specific nasal hyperreactivity after allergen challenge in patients with perennial allergic rhinitis. Allergol Int. 1998;47:59–67.CrossRef
59.
Johnston SL, Smith S, Harrison J, et al. The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage. J Allergy Clin Immunol. 1993;91:903–9.CrossRefPubMed
60.
Aizawa H, Shigyo M, Nogami H, et al. BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest. 1996;109(2):338–42.CrossRefPubMed
61.
Philip G, van Adelsberg J, Loeys T, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009;124:942–8.CrossRefPubMed
62.
Van Hecken A, Depre M, De Lepeleire I, et al. The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol. 2007;63:135–41.CrossRefPubMed
63.
Oguma T, Palmer LJ, Birben E, et al. Role of prostanoid DP receptor variants in susceptibility to asthma. N Engl J Med. 2004;351:1752–63.CrossRefPubMed
64.
65.
Busse WW, Wenzel SE, Meltzer EO, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol. 2013;131:339–45.CrossRefPubMed
66.
Nishikawa-Shimoto R, Sekiguchi Y, Koami T, et al. Isoquinoline derivatives as potent CRTH2 receptor antagonists: synthesis and SAR. Bioorgan Med Chem Lett. 2012;22:3305–10.CrossRef
67.
Luker T, Bonnert R, Brough S, et al. Substituted indole-1-acetic acids as potent and selective CRTH2 antagonists—discovery of AZD1981. Bioorgan Med Chem Lett. 2011;21:6288–92.CrossRef
68.
Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41:46–52.CrossRefPubMed
69.
Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67:1572–9.PubMed
70.
Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2011;42:38–48.CrossRefPubMed
71.
Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69(9):1223–32.CrossRefPubMed
72.
Kuna P, Bjermer L, Tornling G. Two phase II randomized trials on the CRTH2 antagonist AZD 1981 in adults with asthma. Drug Des Dev Ther. 2016;10:1–12.CrossRef
73.
Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37–44.CrossRefPubMed
74.
Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects. Fundam Clin Pharmacol. 2014;28:690–9.CrossRefPubMed
75.
Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44:1044–52.CrossRefPubMed
76.
Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–54.CrossRefPubMedPubMedCentral
Metadata
Title
Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives
Authors
Maciej Kupczyk
Piotr Kuna
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0777-2

Other articles of this Issue 12/2017

Drugs 12/2017 Go to the issue

Adis Drug Evaluation

Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes

Leading Article

Drugs in Development for Hepatitis B

Review Article

Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal

Review Article

Therapeutic Utility of Opioids for Restless Legs Syndrome

AdisInsight Report

Durvalumab: First Global Approval

AdisInsight Report

Abaloparatide: First Global Approval